3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
12
Carcinoma, Intraductal, Noninfiltrating
2
Breast Neoplasms, Male
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sexual Dysfunctions, Psychological
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Breast Carcinoma In Situ
1
Anatomic Stage II Breast Cancer AJCC v8
1
Advanced Breast Cancer
1
Interventions
pembrolizumab
14
Paclitaxel
13
Carboplatin
12
Bevacizumab
7
Specimen Handling
6
Cisplatin
6
olaparib
5
Taxes
5
Fulvestrant
5
Nivolumab
4
Megestrol Acetate
4
Magnetic Resonance Spectroscopy
4
Biopsy
4
palbociclib
3
durvalumab
3
Oxaliplatin
3
Leucovorin
3
Letrozole
3
Immunoglobulin G
3
Fluorouracil
3
Doxorubicin
3
Docetaxel
3
Disulfides
3
trastuzumab deruxtecan
2
ribociclib
2
pertuzumab
2
lenvatinib
2
ipatasertib
2
dostarlimab
2
capivasertib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
exemestane
×
30 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled